Beyond the Scale: Rutgers Study Links GLP-1 Medications to Reductions in Violent Impulses
Popular GLP-1 receptor agonists—most notably Ozempic and Wegovy—have fundamentally reshaped the landscape of metabolic medicine. Initially approved for the management of type 2 diabetes and subsequently heralded as a breakthrough in obesity treatment,…